News | May 29, 2023
Wockhardt’s Q4 FY23 three fold jump in EBITDA over Q4 FY22
Two patents were filed during the quarter ended 31st March, 2023 and the cumulative filings till date are 3239
Two patents were filed during the quarter ended 31st March, 2023 and the cumulative filings till date are 3239
Aim of the agreement is to expand the full potential of Beren’s cyclodextrin technologies and their medicinal applications.
The company has reported total income of Rs. 11303.95 crores during the period ended March 31, 2023
For Q4 ended FY23, company reported net profit of Rs. 12.56 crore as against net profit of Rs. 11.02 crore in the corresponding period last year
Operating EBITDA increased by 21% to INR 181 crores in Q4 FY23
The drug discovery of mRNA-targeted small molecules is rapidly gaining attention due to the current difficulty of developing drugs against conventional protein targets
The USFDA had classified Strides Puducherry facility as OAI in May 2019 followed by issuing a warning letter to this site in July 2019.
Single dose of Ferric Carboxymaltose (FCM) up to 750 mg of iron can be infused in 15 minutes
The facility will have a capacity to manufacture upto 3 million tubes monthly
The addition of these two hospitals will provide increased access to specialized pediatric and perinatal care services in the geography
Subscribe To Our Newsletter & Stay Updated
